75 related articles for article (PubMed ID: 9152416)
21. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target.
Armstrong SJ; Dimmock NJ
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1397-402. PubMed ID: 8757979
[TBL] [Abstract][Full Text] [Related]
22. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1.
Schutten M; Andeweg AC; Bosch ML; Osterhaus AD
Scand J Immunol; 1995 Jan; 41(1):18-22. PubMed ID: 7824885
[TBL] [Abstract][Full Text] [Related]
24. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity.
Si Z; Phan N; Kiprilov E; Sodroski J
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):217-26. PubMed ID: 12689414
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.
Robinson WE; Kawamura T; Lake D; Masuho Y; Mitchell WM; Hersh EM
J Virol; 1990 Nov; 64(11):5301-5. PubMed ID: 1698995
[TBL] [Abstract][Full Text] [Related]
26. Anti-human immunodeficiency virus-1 antibody titers in injection drug users compared to sexually infected individuals.
Bongertz V; Ouverney EP; Teixeira SL; Silva-de-Jesus C; Hacker MA; Morgado MG; Bastos FI
Mem Inst Oswaldo Cruz; 2003 Mar; 98(2):209-12. PubMed ID: 12764435
[TBL] [Abstract][Full Text] [Related]
27. Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1.
Gauduin MC; Weir R; Fung MS; Koup RA
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):205-11. PubMed ID: 9491910
[TBL] [Abstract][Full Text] [Related]
28. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.
Robinson WE; Gorny MK; Xu JY; Mitchell WM; Zolla-Pazner S
J Virol; 1991 Aug; 65(8):4169-76. PubMed ID: 2072448
[TBL] [Abstract][Full Text] [Related]
29. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.
Günthard HF; Gowland PL; Schüpbach J; Fung MS; Böni J; Liou RS; Chang NT; Grob P; Graepel P; Braun DG
J Infect Dis; 1994 Dec; 170(6):1384-93. PubMed ID: 7995976
[TBL] [Abstract][Full Text] [Related]
30. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
Buchbinder A; Zolla-Pazner S; Karwowska S; Gorny MK; Burda ST
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1395. PubMed ID: 1466965
[No Abstract] [Full Text] [Related]
31. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
Kostrikis LG; Cao Y; Ngai H; Moore JP; Ho DD
J Virol; 1996 Jan; 70(1):445-58. PubMed ID: 8523557
[TBL] [Abstract][Full Text] [Related]
32. An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.
Heap CJ; Reading SA; Dimmock NJ
J Gen Virol; 2005 May; 86(Pt 5):1499-1507. PubMed ID: 15831963
[TBL] [Abstract][Full Text] [Related]
33. Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody.
Mabondzo A; Boussin F; Raoul H; Le Naour R; Gras G; Vaslin B; Bartholeyns J; Romet-Lemonne JL; Dormont D
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1451-6. PubMed ID: 8207409
[TBL] [Abstract][Full Text] [Related]
34. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
Gauduin MC; Safrit JT; Weir R; Fung MS; Koup RA
J Infect Dis; 1995 May; 171(5):1203-9. PubMed ID: 7751695
[TBL] [Abstract][Full Text] [Related]
35. Antibody-based inhibitors of HIV infection.
Choudhry V; Zhang MY; Dimitrova D; Prabakaran P; Dimitrov AS; Fouts TR; Dimitrov DS
Expert Opin Biol Ther; 2006 May; 6(5):523-31. PubMed ID: 16610981
[TBL] [Abstract][Full Text] [Related]
36. Simplified conjugation chemistry for coupling peptides to F(ab') fragments: autologous red cell agglutination assay for HIV-1 antibodies.
Wilson KM; Catimel B; Mitchelhill KI; Kemp BE
J Immunol Methods; 1994 Oct; 175(2):267-73. PubMed ID: 7930654
[TBL] [Abstract][Full Text] [Related]
37. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.
De Vreese K; Reymen D; Griffin P; Steinkasserer A; Werner G; Bridger GJ; Esté J; James W; Henson GW; Desmyter J; Anné J; De Clercq I
Antiviral Res; 1996 Mar; 29(2-3):209-19. PubMed ID: 8739600
[TBL] [Abstract][Full Text] [Related]
38. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection.
Prohászka Z; Nemes J; Hidvégi T; Tóth FD; Kerekes K; Erdei A; Szabó J; Ujhelyi E; Thielens N; Dierich MP; Späth P; Ghebrehiwet B; Hampl H; Kiss J; Arlaud G; Füst G
AIDS; 1997 Jul; 11(8):949-58. PubMed ID: 9223728
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41.
Chen YH; Böck G; Vornhagen R; Steindl F; Katinger H; Dierich MP
Mol Immunol; 1994 Sep; 31(13):977-82. PubMed ID: 8084338
[TBL] [Abstract][Full Text] [Related]
40. Application of monoclonal antibodies to monitor the synthesis of a glycoprotein core of envelope glycoproteins of human immunodeficiency virus (HIV-1).
Jagodzinski PP; Trzeciak WH
Biomed Pharmacother; 2000 Feb; 54(1):50-3. PubMed ID: 10721463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
